Trial record 3 of 17 for:    Albinism

The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism (LUVIA)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2014 by Johns Hopkins University
Sponsor:
Collaborator:
Clark Charitable Foundation, Inc
Information provided by (Responsible Party):
Dr. Hendrik PN Scholl, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT02200263
First received: July 23, 2014
Last updated: July 24, 2014
Last verified: July 2014
  Purpose

The LUVIA study is a randomized placebo-controlled trial designed to investigate the effects of lutein and zeaxanthin supplementation on macular pigment and visual function in ocular or oculocutaneous albinism. Lutein and zeaxanthin supplementation will be compared to a placebo (no treatment) gel pill over the period of 12 months, with study visits approximately every 3 months for the first year and a final visit 18 months after enrollment.


Condition Intervention
Ocular Albinism (OA)
Oculocutaneous Albinism (OCA)
Dietary Supplement: Lutein plus Zeaxanthin
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Placebo-controlled Trial to Investigate the Effect of Lutein and Zeaxanthin Supplementation on Macular Pigment and Visual Function in Albinism - LUtein for VIsion in Albinism (LUVIA)

Resource links provided by NLM:


Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • Macular pigment optical density (MPOD) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    MPOD will be measured at baseline and follow-up. MPOD will be evaluated psychophysically using the QuantifEye device (ZeaVision), optically using the MPOD module of the Heidelberg Spectralis multicolor imaging device, and by quantitative fundus autofluorescence (FAF) using the Heidelberg Spectralis multicolor imaging device


Secondary Outcome Measures:
  • Contrast acuity [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Contrast acuity will be measured at baseline and follow-up using the Innova electronic visual system and the quick Contrast Sensitivity Function (Adaptive Sensory Technology, LLC)

  • Visual field, fixation and central retinal sensitivity [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Microperimetry testing via the microperimetry (MP) -1 device (Nidek) will be performed at baseline and follow-up

  • Bioavailability profile of Lutein and Zeaxanthin [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Blood samples will be collected at follow-up, and Lutein and Zeaxanthin concentration levels assessed.

  • Evaluation of the diversity of microstructural central retinal abnormalities [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Spectral domain ocular coherence tomography (SD-OCT) macular scan will be performed at baseline and at 12 months

  • Best Corrected Visual Acuity (BCVA) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    BCVA will evaluated using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at baseline and follow-up


Estimated Enrollment: 28
Study Start Date: September 2014
Estimated Study Completion Date: September 2018
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lutein plus Zeaxanthin
Participants randomized to this arm will receive 20 mg of Lutein (L) plus 20 mg of Zeaxanthin (Z) per day: Two pills (10 mg L+ 10 mg Z per pill) for the duration of one year.
Dietary Supplement: Lutein plus Zeaxanthin
dose: two softgels once a day with a meal
Other Name: EyePromise® Lutein + Zeaxanthin (ZeaVision, LLC)
Placebo Comparator: Placebo softgels
Participants randomized to this arm will receive two pills per day of placebo-gels corresponding to the active compound in look and feel for the duration of one year
Dietary Supplement: Placebo
two softgels once-daily with a meal
Other Name: placebo softgels

Detailed Description:

Ocular and oculocutaneous albinism represent a spectrum of disorders with absent or significantly diminished amount of melanin either across different body tissues - skin, hair, eye (Oculocutaneous Albinism 1 and 2), or exclusively in eye tissues only (Ocular Albinism 1) .

The functionality and the clinical findings are diverse (the phenotype), and no direct correlation has been established to the underlying mutations (genotype).

The common ocular phenotype includes iris transillumination, foveal hypoplasia, nystagmus, reduced visual acuity, refractive error, photosensitivity and abnormal development of the visual pathways with characteristic abnormal routing of ganglion cell axons in the chiasma, resulting in abnormal visually evoked potentials. Current treatment options are limited to optical methods and low vision aids.

The mechanism of melanin pigment formation in the RPE cells and its role in the visual pathways and structures development is not completely understood, but a correlation was found between the amount of fundus pigmentation and visual function in albino patients. The absent pigmentation within the retinal pigment epithelium (RPE) may thus contribute to visual performance deficits.

The macular pigment (MP) consists of two main carotenoids, lutein and zeaxanthin, which are concentrated in the macular region of the retina. MP is hypothesized to function via a protective mechanism by absorbing blue light incident on the retina thereby reducing oxidative damage to the underlying photoreceptors. It is also thought to improve visual function via reduction of chromatic aberration and glare. It is currently unclear as to how the variability in macular pigment optical density (MPOD) affects congenital retinal conditions. The MP would, however, be a hypothetical and good candidate to improve visual performance - simply by increasing pigmentation, reducing light scatter and thus glare sensitivity.

As this pigment is not produced in the retina, but is absorbed via diet, it can be manipulated by alteration in diet and supplementation thereby providing potential therapy for retinal diseases. It is however necessary first to see if MPOD levels are measurable in this disorder before dietary advice can be provided after completion of the LUVIA study. Further to this, evaluation of both the structural and functional properties of the retina will provide greater insight into the possible function of MP in this retinal disease including whether supplementation would be of benefit.

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age of 12 years old and older
  2. Clinical and/or genetic diagnosis of ocular or oculocutaneous albinism
  3. Ocular media allowing acceptable visualization of the retina.
  4. Ocular media allowing acceptable quality of the ocular coherence tomography (OCT) and/or fundus autofluorescence (FAF) scans.
  5. At least one reliable central macular pigment optical density (MPOD) measurement captured on the enrollment visit in at least one eligible eye
  6. Best corrected visual acuity of 20/200 or better in one or both eligible eyes (eyes that confirmed to be eligible by the MPOD testing).

Exclusion Criteria:

  1. Persons taking lutein plus zeaxanthin supplements over the past 6 months
  2. Pregnant or planning to become pregnant
  3. Evidence of present or past retinal macular condition other than congenital foveal hypoplasia
  4. History of gastrointestinal disease that would interfere with absorption of lutein and zeaxanthin
  5. Participation in a clinical trial requiring visual testing or administration of a drug (marketed or investigational) within 60 days before entry in the study (the day informed consent is signed)
  6. Inability to communicate or cooperate with the investigator due to cognitive impairment or poor general health
  7. Any other condition which, in the opinion of the investigators, is likely to interfere with the successful collection of the measures required for the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02200263

Contacts
Contact: Yulia Wolfson, MD 443-287-1874 ywolfso1@jhmi.edu

Locations
United States, Maryland
Wilmer Eye Institute Not yet recruiting
Baltimore, Maryland, United States, 21287-9277
Contact: Yulia Wolfson, MD       ywolfso1@jhmi.edu   
Principal Investigator: Hendrik P. Scholl, MD         
Sub-Investigator: Yulia Wolfson, MD         
Sponsors and Collaborators
Johns Hopkins University
Clark Charitable Foundation, Inc
Investigators
Principal Investigator: Hendrik P. Scholl, MD Johns Hopkins University
Study Director: Yulia Wolfson, MD Johns Hopkins University
  More Information

No publications provided

Responsible Party: Dr. Hendrik PN Scholl, Professor, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT02200263     History of Changes
Other Study ID Numbers: NA_00088335
Study First Received: July 23, 2014
Last Updated: July 24, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Johns Hopkins University:
ocular albinism (OA)
oculocutaneous albinism (OCA)
macular pigment
visual function

Additional relevant MeSH terms:
Albinism
Albinism, Ocular
Albinism, Oculocutaneous
Eye Diseases, Hereditary
Eye Diseases
Genetic Diseases, Inborn
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Skin Diseases, Genetic
Hypopigmentation
Pigmentation Disorders
Skin Diseases
Metabolic Diseases

ClinicalTrials.gov processed this record on July 26, 2014